Boulder biotech shares rise with 'positive' melanoma drug results
Shares in Array BioPharma Inc. were soaring in early Wednesday trading, even though the company announced a bigger loss and smaller third-quarter revenues compared with last year.
That's because the Boulder biotech announced "positive" results from a study of its drug targeting unresectable or metastatic melanoma.
The study results "represents a potential important addition to the ... treatment landscape for patients with BRAF-mutant melanoma," said Ron Squarer, CEO, in a statement.
Array said…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Ben Miller Source Type: news
More News: Biotechnology | Health Management | Melanoma | Pharmaceuticals | Profits and Losses | Skin Cancer | Study